Edgemon James, CFO and Treasurer, has demonstrated a clear bias toward selling shares in United Therapeutics Corporation (UTHR), as evidenced by SEC Form 4 filings. Over the course of 138 trades, James has sold shares totaling $81,142,412.50, compared to purchases of $22,975,967.51. This trend has intensified recently, with 24 consecutive sell transactions recorded in March 2026, amounting to significant sums. Notably, on March 30, 2026, James executed multiple sales, ranging from $12,737.13 to $874,974.44, culminating in a single transaction valued at $1,354,200. Earlier in the same month, on March 26, 2026, additional sales were reported, including transactions worth $535,679.92 and $846,688.93.
James’s trading activity is exclusively tied to United Therapeutics, indicating a concentrated focus on this single company. The absence of recent buy transactions underscores a consistent divestment strategy, with no indication of reacquisition during this period. While the reasons behind these sales remain undisclosed, the pattern aligns with a broader trend of reducing holdings in UTHR. The sheer volume and frequency of these transactions highlight James’s active management of his equity position in the company, reflecting a sustained and deliberate approach to share disposition.
AI-assisted summary